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Introduction
Pseudohypoparathyroidism (PHP) represents a heteroge-
neous group of disorders characterized by end-organ unres-
ponsiveness to PTH leading to hypocalcemia, hyperphospha-
temia, and elevated PTH concentrations. PHP is divided into
types 1a, 1b, 1c and type 2 that differ with respect to 
phenotype and hormone resistance patterns. PHP type 1 is
associated with a diminished urinary cAMP and phophaturic
response to exogenous PTH administration (1). In addition to
hormone resistance, patients with PHP type 1a also display a
constellation of findings known as Albright hereditary 
osteodystrophy (AHO). AHO may be characterized by short
stature, round facies, brachydactyly, obesity, ectopic soft 
tissue or dermal ossification (osteoma cutis), developmental
delay and reduced Gsα activity (2). The features of AHO are
also present in pseudopseudohypoparathyroidism (PPHP),
but PPHP differs in that there is no associated hormone 
resistance. PHP 1b is characterized by PTH-resistance with
hypocalcemia and hyperphosphatemia but without the features
of AHO. Patients with PHP1c differ from PHP1a patients in
that they have multiple hormone resistance but normal Gsα
activity. Finally, patients with PHP2 have a normal cAMP 
response to PTH but have an impaired phosphaturic response.
We herein report a case of PHP1a presenting with 
congenital hypothyroidism, PHP, osteoma cutis, obesity and
psychomotor retardation. These manifestations of PHP1a 
resulted from a novel mutation in the guanine nucleotide-binding
protein, alpha-stimulating activity polypeptide 1 (GNAS1) gene.
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The proband was born full term via cesarean section. His
birth weight was 3458 g and length was 50cm. His mother
had an uncomplicated pregnancy. He was found to be jaundiced
on day three of life with resolution of his hyperbilirubinemia 
after 24 hours of phototherapy. Neonatal thyroid function
screening revealed a plasma total thyroxine of 8.6 ug/dL (normal
range 10 to 20  ug/dl) and an elevated thyroid stimulating 
hormone (TSH) of 32 uU/mL (normal range <20 uU/mL) on
post natal day 2, compatible with congenital hypothyroidism.
On initial examination at three weeks of age, the patient’s
weight was 3855 g. Physical findings, with the exception of an
umbilical hernia, were unremarkable. The anterior fontanel was
open and the posterior fontanel was closed. There was no 
goiter. There was no hypotonia. He had normal prepubertal 
male genitalia with descended testes bilaterally. The patient
was started on Levothyroxine 25 micrograms, at 3 weeks of
age, at which time his free T4 was 1.0 ng/dl (normal range 0.8
to 2.2 ug/dl) and his TSH was 12.8 uU/mL (normal range 0.5 to
4.5 uU/mL). A sonogram of the neck was performed at 5 
weeks of age which showed a right thyroid lobe measuring 
approximately 15 x 8 x 8 mm (right thyroid lobe volume of 0.5 cc).
There was a solitary nodule in the mid aspect of the right lobe
of the thyroid measuring 5.0 x 3.0 x 4.0 mm. The left lobe of the
thyroid measured 12 x 7 x 7 mm, (left thyroid lobe volume of
0.3cc) with no nodules identified. A repeat sonography at 8
months of age showed a stable appearance of the right lobe 
nodule. 
At 17 months of age, subcutaneous ossification was noted
on the left thumb. Subsequent radiologic examination of the
hands showed an area of calcification at the left first metacarpal-
phalangeal joint as well as diffuse osteopenia,  and an advanced
bone age of 4 years at a chronologic age of 26 months. 
Serum biochemistry  at 21, 25 and 28 months of age revealed
PTH levels of  98, 228 and 237 pg/mL respectively (normal
range 15-75 pg/ml), marginally elevated phosphate levels
(6.7, 6.5 and 6.3 mg/dL, normal range 4.5-5.5 mg/dL) and 
calcium levels of 10.1, 9.5 and 9.3 mg/dL (normal range 8.3-
10.3 mg/dl). The 25-hydroxy vitamin D level was 27 ng/ml
(normal range 30-80 ng/ml) and 1,25-dihydroxy vitamin D 
level was 64 pg/ml (normal range 15-75 pg/ml) at 27 months. 
A review of the patient’s growth data revealed that his
height corresponded to 81st centile for age (Z score 0.864) at
13 months of age and to 76th percentile (Z score 0.706) at 25
months of age. His weight centiles changed from 86th centile
(Z score 1.084) to over 99th centile (Z score 2.377) in the 
same period.  His body mass index at 25 months of age was
20.7 kg/m
2 (>97th centile, Z score 2.31). 
The patient showed a delayed motor and language 
development and he is currently receiving occupational 
therapy, speech therapy and special education. 
The patient’s mother also showed features of AHO 
including obesity, short 4th and 5th metacarpal bones with
multiple areas of ectopic calcium deposits which were 
present for 21 years and were non progressive. There was
no evidence of hormone resistance in the mother; her PTH
was 31.5 pg/ml (normal range 10-65 pg/ml). 
G Ge en ne et ti ic c   S St tu ud dy y   R Re es su ul lt ts s
Mutations in the gene encoding Gsα (GNAS1) were 
investigated by polymerase chain reaction (PCR) and DNA 
sequencing of exons 1 (codon 7-43) through 13. A novel 
mutation, c.1100_1102insA, was detected in exon 13 which
resulted in a frameshift and premature termination, 10 amino
acids downstream. This mutation was also identified in the 
patient’s mother. This alteration is not considered as a 
polymorphism.
Discussion
PHP has been linked to mutations in the gene encoding
the alpha subunit of the stimulatory G protein (GNAS1),
which maps to 20q13.2. The inheritance pattern appears to
be autosomal dominant and displays variable penetrance.
The GNAS1 locus is very complex and gives rise to Gsα and
several other splice variants (3,4). Estimates of the proportion
of AHO caused by GNAS1 mutations range from 60 to 90%.
These mutations have been described throughout the 13
exon gene. Approximately 35 to 50% of reported mutations
are 4 bp deletions in exon 7 and this seems to be an area of
increased susceptibility. Mutations in exons 7-10 comprise
35-50% of all mutations (5). 
Gsα is ubiquitously expressed and its deficiency results in
resistance to PTH as well as to other hormones that signal
through G protein coupled receptors such as TSH and 
gonadotropins  (6,7). Interestingly, although vasopressin and
adrenocorticotropic hormone (ACTH) also signal via G protein
coupled receptors, resistance to their actions has not been 
observed in patients with PHP1a. (7). The haploinsufficiency of
the GNAS1 gene is tissue specific and in most tissues 
transcription occurs equally from both alleles. However, in a
subset of tissues such as the proximal renal tubules, anterior
pituitary, thyroid gland and ovary, expression is monoallelic and
is restricted to the maternal allele. This may help elucidate the
selective resistance to hormones observed in patients with
PHP (3,8).  
In our case, we present two individuals (the proband and
his mother) with identical GNAS1 mutations who display the
characteristic features of AHO, however differ in their 
resistance to multiple hormones. This finding can be explained
by genomic imprinting of Gsα in which maternal transmission
leads to offspring with PHP1a whereas paternal transmission
leads to offspring with PPHP, as was the case in the patient’s
mother. Tissue specific imprinting in addition to "parent of
origin" imprinting explains why Gsα expression is equally 
reduced in PHP1a and PPHP yet only maternal transmission
results in proximal renal tubule resistance to PTH (9).
Congenital hypothyroidism has been reported as the 
presenting manifestation of PHP (6,10,11). TSH levels are
typically elevated at birth but may then normalize for a period
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resistance to TSH is generally mild, and this may be explained
by partial imprinting in the thyroid with incomplete silencing
of the paternal allele (8). Goiter is typically absent given that
the defect lies in TSH signaling (12) and antithyroid antibodies
are also absent (9). A very small thyroid nodule was present
since birth in our patient. Although unclear, it may be possible
that this thyroid nodule could be linked to TSH resistance.
The terms calcinosis cutis and osteoma cutis are often
used interchangeably in the literature when describing the
subcutaneous manifestation of PHP1a. Calcinosis cutis 
differs from osteoma cutis in that it describes a group of 
disorders in which insoluble compounds of calcium are 
deposited within the skin rather than true bone (as is the 
case in osteoma cutis). Ectopic bone formation (osteoma 
cutis and progressive osseous heteroplasia) has been observed
in patients with AHO. Progressive osseous heteroplasia
(POH) is a form of heterotopic ossification (HO) that progresses
from superficial tissues into the deeper connective tissues
including muscle and fascia but is not associated with AHO
or hormone resistance. It is caused by paternal inheritance of
the GNAS1 mutation (13). These syndromes are all associated
with heterozygous mutations in GNAS1 which leads to 
decreased expression or function of Gsα.  This decreased
Gsα activity has been directly linked to osteogenic differentiation
in human mesenchymal cells and this finding provides a 
potential explanation for the ectopic bone formation in these
syndromes (14). This results in a spectrum of extra-skeletal
ossification disorders with POH and progressive heterotopic
ossification syndromes lying at the far end of the phenotypic
spectrum. Although PHP1a is typically associated with a non
progressive form of heterotopic ossification, PHP1a with a
progressive form of HO has been described (15). There is no
specific genotype-phenotype correlation that distinguishes
the non progressive forms of heterotopic ossification from
the progressive forms (13). 
The pathogenesis of calcinosis cutis is not completely 
understood and it may develop in response to local and/or
systemic factors such as collagen vascular diseases, 
cutaneous neoplasms, infections and trauma (16). Given that
calcinosis cutis is not found in patients with primary 
hypoparathyroidism, it is less likely that hypocalcemia and
hyperphosphatemia are contributing to this clinical picture
(17). Moreover, in case reports describing calcinosis cutis in
patients with PHP1a, the calcium levels were normal or only
marginally above reference values (17,18). Intracranial 
calcifications and cataracts have also been observed in 
patients with hypoparathyroidism and PHP. Unlike calcinosis
cutis, these calcifications do appear to be caused by the
hypocalcemia and hyperphosphatemia (1). It is unclear if 
calcinosis cutis lies at the milder end of the spectrum of 
heterotopic ossification. Besides osteoma cutis, other features
of AHO may include obesity, psychomotor retardation and
tall stature with advanced bone age. Studies have implicated
haploinsufficiency of Gsα as a cause of accelerated differen-
tiation of chondrocytes and osteoblasts and premature 
epiphyseal fusion leading to an advanced bone age (8). 
The mainstay of treatment for PHP involves the administra-
tion of oral calcium and 1 α-hydroxylated vitamin D metabolites,
such as calcitriol. This therapy should be initiated in every 
patient with a diagnosis of PHP with the goal of maintaining
serum total and ionized calcium levels within the reference
range to avoid hypercalciuria and to maintain PTH levels in
the normal range. PTH indirectly activates osteoclasts which
are involved in bone resorption and accelerates bone 
remodeling. In patients with PHP there is variable responsi-
veness of the skeleton to PTH despite clinical evidence of
impaired hormone responsiveness in other tissues including
the kidney (19). In the absence of skeletal osteoclast 
resistance to PTH, hyperparathyroid bone disease such as
osteopenia or osteitis fibrosa may develop. Therefore, it is
important to maintain PTH in the normal/upper normal range
even in the asymptomatic normocalcemic patient (20,21).
Skeletal responsiveness to PTH may help explain the periods
of spontaneous normocalcemia observed in some patients
(19). The finding of elevated PTH levels in the context of 
normocalcemia suggests that hypocalcemia may not be the
only factor leading to hyperparathyroidism in PHP. Factors
contributing to the hyperparathyroidism in PHP may include
frequent small unrecognized declines in the serum calcium
concentration in addition to a reduction in 1,25-dihydroxy-
vitamin D. Other suggested explanations include secretion of
an abnormal PTH, or abnormal metabolism of PTH (22). 
In summary, we report a case of PHP 1A presenting with
congenital hypothyroidism with a small thyroid nodule and
osteoma cutis. The Gs-α mutation can present with variable
effects on phenotype and clinical clues provide valuable 
information.  
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